Emergent BioSolutions

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Emergent BioSolutions addresses revenue challenges, eyes market expansion opportunities

Emergent BioSolutions navigated revenue challenges in Q4 2022, focusing on core businesses and strategic initiatives with a strong financial outlook for 2023.
The company faces competition and market positioning challenges in the OTC space for NARCAN, while opportunities exist in market expansion and government contracts.
Balancing pricing strategies, securing procurement decisions, and extending credit facility maturity are key focus areas for sustained growth and profitability.
Overall, Emergent BioSolutions demonstrates resilience and adaptability in addressing market challenges while capitalizing on opportunities for growth and market expansion.

Emergent BioSolutions (EBS) excels in Q1 with FDA approvals and strategic sales

Emergent BioSolutions (EBS) delivered a robust Q1 performance with notable achievements in FDA approvals and strategic business decisions. While facing challenges in gross margin changes and insurance coverage discussions, EBS remains focused on growth opportunities and product innovation.

Emergent BioSolutions reports Q2 growth, shifts focus to core products

Emergent BioSolutions' Q2 2023 earnings call highlighted positive financial results, strong NARCAN Nasal Spray sales, and strategic shifts towards core products. The company provided updated guidance for 2023, focusing on revenue expectations and cost-saving measures. Analyst questions centered on revenue breakdown, restructuring efforts, and future growth prospects.

Emergent BioSolutions (EBS) exceeds Q3 expectations, focuses on growth

Emergent BioSolutions (EBS) demonstrated strong financial performance in Q3 2023, exceeding revenue and EBITDA expectations. The company's focus on core products, compliance, and cost reduction initiatives positions it well for future growth. Challenges include a rescheduled earnings release and the need to meet growing demand for NARCAN Nasal Spray.

Emergent BioSolutions reports solid Q4 performance and outlines growth strategies

Emergent BioSolutions showcased strong financial performance and operational progress in Q4 2023, setting the stage for a promising 2024.
The company's strategic focus on debt reduction, quality enhancement, and core product strength bodes well for future growth.
While challenges persist in managing product sales variability and addressing stakeholder inquiries, opportunities for expansion and success are abundant.

Emergent BioSolutions excels in Q1, raises 2024 outlook amid growth prospects

Emergent BioSolutions reported strong Q1 performance, raised profit outlook for 2024, and highlighted growth drivers for key products. The company's strategic actions to reduce costs, improve profitability, and focus on core businesses demonstrate a proactive approach to driving long-term value. Despite challenges like potential generic competition, EBS remains well-positioned to leverage growth opportunities and sustain its positive momentum.

Emergent BioSolutions (EBS) exceeds Q2 guidance, poised for growth

Emergent BioSolutions (EBS) delivered strong Q2 results, exceeding revenue guidance and showcasing operational improvements.
The company's strategic actions, product highlights, and financial performance position it well for future growth and value creation.
Challenges in revenue sustainability and operational changes exist, but opportunities in international expansion, partnerships, and innovation are key drivers.
Overall, Emergent's focus on public health preparedness, opioid crisis solutions, and strategic growth initiatives bode well for its long-term success.

Emergent BioSolutions excels in Q3, poised for growth opportunities

Emergent BioSolutions delivered a strong Q3 performance, showcasing financial resilience, operational excellence, and strategic advancements across key business segments.
While facing challenges in pricing dynamics and revenue mix, the company's focus on growth opportunities, compliance, and leadership appointments positions them for sustained success.
With a solid financial foundation, improved guidance, and a strategic roadmap for growth, Emergent is well-equipped to navigate challenges, capitalize on opportunities, and drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GAITHERSBURG, Md., May 10, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2024 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 23, 2024 at 9:00 am eastern time.

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024

Emergent BioSolutions (NYSE: EBS ) layoffs are in the news as the life sciences company prepares to cut jobs and close down certain facilities. According to a release from Emergent BioSolutions, these layoffs will affect 300 of its employees.

Emergent BioSolutions Layoffs 2024: What to Know About the Latest EBS Job Cuts

Emergent BioSolutions (NYSE: EBS ) stock is taking off on Thursday after surprising investors with strong Q1 2024 earnings results. The life sciences company reported adjusted earnings per share of 59 cents for the quarter.

Why Is Emergent BioSolutions (EBS) Stock Up 57% Today?

Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2024 Earnings Call Transcript May 1, 2024 5:00 PM ET Company Participants Joe Papa - President and CEO Rich Lindahl - EVP and CFO Paul Williams - SVP, Products Business Operator Good afternoon, everyone. I'm the operator for today's call.

Emergent BioSolutions Inc. (EBS) Q1 2024 Earnings Call Transcript

Emergent BioSolutions is closing several manufacturing facilities and cutting hundreds of jobs as part of a restructuring as the company narrows its focus on products, including Narcan nasal spray.

Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2024.

Emergent BioSolutions Reports First Quarter 2024 Financial Results

Emergent BioSolutions said on Wednesday that it would cut about 300 jobs across all areas of the company and shut down several manufacturing facilities as part of a restructuring plan.

Emergent BioSolutions to lay off about 300 employees

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced the next phase of its new operational plan that consolidates operations, closes several manufacturing facilities, and restructures its enterprise workforce to improve the performance and profitability of its business. Emergent will continue to focus on its core products business – medical countermeasures and NARCAN® Nasal Spray –and on delivering for its patients and customers, including the U.S. and allied governments.

Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position

GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the results of a new national public opinion survey showing that more than 90 percent of Americans surveyed recognize opioid overdoses are a pressing concern for teenagers and college students, and more than 9 in 10 parents in the survey agree schools should do more to educate on the risks of opioids and how to respond to an overdose.

Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility.

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.

Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024

GAITHERSBURG, Md., March 28, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to fighting the ongoing opioid crisis by broadening access to, and awareness of, NARCAN® Nasal Spray to help save lives in opioid overdose emergencies. In 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported over 107,000 overdose deaths – a number that has risen almost every year and which has continued to break annual records.1 This includes a rise in synthetic opioid overdoses mainly driven by fentanyl.1 There is an inherent risk of potential overdose, wherever opioids are present, which has tragically become the leading cause of accidental death in the U.S.2 These statistics only further underscore the need for multi-sectoral action to address and prevent opioid overdose deaths.

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility. Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP).

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales

Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2023 Earnings Conference Call March 6, 2024 5:00 PM ET Company Participants Rich Lindahl - Executive Vice President & Chief Financial Officer Joe Papa - President and Chief Executive Officer Paul Williams - Senior Vice President & Head, Products Business Conference Call Participants Jessica Fye - JPMorgan Frank DiLorenzo - Singular Research Operator Good afternoon, everyone. I'm the operator for today's call.

Emergent BioSolutions Inc. (EBS) Q4 2023 Earnings Call Transcript

Emergent Biosolutions (EBS) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.31 per share a year ago.

Emergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates

GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent's newly appointed president and CEO, Joseph C. Papa, will provide remarks.

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

It's quite possible to see scenarios where EBS trades well above its current price, but a chance of wipe-out remains too.

New CEO Appointment A Clear Positive For Emergent BioSolutions

In today's market, one of the biggest winners generating outsized interest is Emergent Biosolutions (NYSE: EBS ). This mid-cap biotech company remains a unique turnaround story for investors, and many appear to be placing their bets on this company to come out of the pile as a key winner.

Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?

GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

Antero Midstream Partners

Aveanna Healthcare Holdings

Dillard's

Con Ed

Harmony Gold Mining Co Ltd

Tellurian

While it's usually a solid principle to bet alongside Wall Street's top experts, sometimes, they don't get it right, which brings us to contrarian analyst picks. You know how I've been supporting my arguments with analyst ratings and price targets?

Contrarian Calls: 7 Analyst ‘Sell' Ratings That Should Be ‘Buys'

Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.

Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine

GAITHERSBURG, Md., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global company providing solutions that address public health threats and brings lifesaving, life-extending products to market, today announced that Haywood Miller, Interim Chief Executive Officer and Rich Lindahl, Chief Financial Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 9:00 a.m. PT.

Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

Emergent BioSolutions stock has a call option-like structure to it and trades as an equity stub currently behind a high debt load. However, business performance may be improving into the important Q4 period, with results coming in February 2024. If historical performance can be regained, then shares are attractively priced at current levels, even assuming material dilution.

News for Emergent BioSolutions Stock (EBS)